Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Pervasive subtypes of pancreatic ductal adenocarcinoma (PDA) and their differing response to therapy.


ABSTRACT: Pancreatic ductal adenocarcinoma (PDA) carries a dismal prognosis and current treatments are only modestly effective. We present evidence that this variation is caused in part by recurrent, pervasive molecular differences between tumors. mRNA expression profiles measured using microdissected PDA clinical samples reveal three dominant subtypes of disease; epithelial, mesenchymal and acinar-like. The classical and quasi-mesenchymal subtypes are observed in human and mouse PDA cell lines. Importantly, responses to cytotoxics and KRAS depletion in human PDA cell lines differ substantially between subtypes, and in opposing directions. Integrated genomics implicate and functional studies support overexpression of the trancription factor GATA6 as a driver of the epithelial subtype. These results provide a molecular framework for evaluating the prospects of personalized treatment in PDA. RNA was extracted from archival patient FFPE PDA samples and hybridized on Affymetrix U133 plus 2.0 microarrays. The CEL files were processed using R based Bioconductor and normalized values were obtained using RMA. RNA was extracted from human PDA cell line samples and hybridized on Affymetrix U133 plus 2.0 microarrays. The CEL files were processed using R based Bioconductor and normalized values were obtained using RMA. RNA was extracted from mouse PDA cell lines and hybridized on Affymetrix Mouse 430a 2.0 microarrays. The CEL files were processed using R based Bioconductor and normalized values were obtained using RMA.

ORGANISM(S): Mus musculus

SUBMITTER: Anguraj Sadanandam 

PROVIDER: E-GEOD-17891 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications


Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically 6 months from diagnosis. Numerous phase 3 trials of agents effective in other malignancies have failed to benefit unselected PDA populations, although patients do occasionally respond. Studies in other solid tumors have shown that heterogeneity in response is determined, in part, by molecular differences between tumors. Furthermore, treatment outcomes are improved by targeting drugs to tumor subtypes in whi  ...[more]

Similar Datasets

2012-07-09 | E-GEOD-30562 | biostudies-arrayexpress
2015-10-30 | E-GEOD-73339 | biostudies-arrayexpress
2010-04-01 | GSE13913 | GEO
2004-10-27 | GSE1873 | GEO
2009-03-31 | E-MEXP-1761 | biostudies-arrayexpress
2014-01-01 | GSE41385 | GEO
2012-03-31 | GSE36897 | GEO
2013-06-24 | E-GEOD-46203 | biostudies-arrayexpress
2011-06-20 | GSE29971 | GEO
2016-01-26 | GSE64819 | GEO